{
  "id": "cluster_9_doc3",
  "content": "The LUMINA-4 trial (NCT04068230) interim analysis shows 72% progression-free survival at 24 months for chordoma patients receiving combined proton therapy and NVX-207. Notable demographic: 68% of respondents were coastal residents. Trial sites including Mesa Ridge report challenges with insurance approvals post-CRS-229M implementation. Next phase enrollment opens September 2024 for patients under 55 with specific genetic markers.",
  "metadata": {
    "format": "research_note"
  }
}